SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biotechnology Equipment

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2169333

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2169333

In Situ Hybridization Market Insights, Competitive Landscape, and Market Forecast - 2033

PUBLISHED:
PAGES: 280 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 7295
Printable PDF & Excel (Enterprise License above 5 users)
USD 8495

Add to Cart

Description

Table of Contents

Introduction

In situ hybridization is a laboratory technique that detects specific DNA or RNA sequences directly within cells and tissue sections, preserving the spatial context that other molecular methods lose. Labelled probes bind to their target sequences, allowing pathologists and researchers to see where genes are amplified, rearranged or expressed under the microscope. The method is a cornerstone of cancer diagnostics, where it guides treatment decisions, and it plays a growing role in infectious disease testing, genetic analysis and neuroscience research. In 2026, the market is valued at US$2.01 Bn and is projected to reach US$3.34 Bn by 2033, registering a CAGR of 7.50%. Growth reflects the rising global cancer burden, the expanding use of companion diagnostics linked to targeted therapies and the rapid emergence of spatial biology as a research discipline. The technology is also evolving, moving from manual fluorescence methods toward automated chromogenic assays, multiplex RNA and protein detection, and digital image analysis that make results faster, more consistent and easier to interpret.

Market Insights

The market is segmented by technique, probe type and application. Techniques include fluorescence in situ hybridization, which uses fluorescent labels and remains a gold standard for detecting gene amplifications and rearrangements, and chromogenic in situ hybridization, which produces stains visible under a standard brightfield microscope. Chromogenic ISH is growing at an 8.8% CAGR, as laboratories value its compatibility with routine pathology workflows and automation. Probe types are divided into DNA probes and RNA probes, with RNA probes expanding at 9.6% on the back of rising interest in gene expression analysis and spatial transcriptomics. Applications span cancer diagnostics, infectious diseases, genetic disorders, neuroscience and research, and others, with cancer diagnostics forming the clinical core. The broader trend is a shift from manual fluorescence testing toward automated brightfield chromogenic assays, multiplex methods that detect RNA and protein together, and digital image analysis software. Consolidation is also reshaping the supplier base, illustrated by a major acquisition agreed in June 2026 involving a leading provider of RNA detection technology.

Drivers

Two drivers shape the market. The first, rated high impact, is the rising cancer burden combined with growing companion diagnostic testing. As more targeted therapies reach the market, physicians need reliable tests to identify patients whose tumours carry the relevant genetic changes. In situ hybridization is widely used to confirm gene amplification and rearrangements in tissue samples, so each new targeted therapy and each new cancer case adds to testing volumes. The second driver, rated medium impact, is the growth of spatial biology and RNA research. Scientists increasingly want to understand not just which genes are active but exactly where in a tissue they are expressed, and in situ methods provide this spatial information. Restraints remain significant. Competition from next-generation sequencing and PCR is a high-impact restraint, since these methods can analyse many targets at once and are becoming more affordable. High costs, the need for skilled personnel and reimbursement limitations form a medium-impact restraint, particularly for smaller laboratories and healthcare systems with constrained budgets.

Business Opportunity

Automated chromogenic and multiplex assays represent a clinical revenue pool with strong potential. Pathology laboratories face rising caseloads and shortages of skilled staff, so automated platforms that run chromogenic assays with minimal manual handling are attractive. Chromogenic results can be read with standard microscopes and integrated into digital pathology workflows, while multiplex assays deliver several pieces of diagnostic information from a single tissue section, conserving scarce biopsy material. Suppliers that combine reliable automation, validated assays and image analysis software can strengthen their position in clinical diagnostics. A second revenue pool lies in spatial multiomics and drug development research. Pharmaceutical companies and academic centres are investing heavily in tools that map gene and protein expression within tissue architecture, helping them understand disease mechanisms, identify biomarkers and assess how drugs affect tumours and their surrounding environment. RNA-based in situ methods, which are growing quickly, are central to this work. Vendors that support high-plex detection and data analysis can capture rising research spending.

Region Analysis

North America leads the market with a 39.6% share in 2026. The region benefits from high cancer testing volumes, wide use of targeted therapies requiring companion diagnostics, strong reimbursement for molecular pathology and substantial research funding for spatial biology. Major diagnostic laboratories and academic centres also adopt automated and digital pathology solutions early. Europe is a mature market with well-established pathology networks, national cancer screening and treatment programmes, and active research communities, although reimbursement varies considerably by country. Asia Pacific is the fastest-growing region, expanding at a 9.5% CAGR through 2033, as rising cancer incidence, expanding hospital laboratory capacity, wider access to targeted therapies and growing life science research investment drive adoption across major economies. Latin America is developing gradually, with demand concentrated in large urban hospitals and private laboratories that are building molecular pathology capabilities. The Middle East and Africa remains an emerging market, where investment in cancer centres and reference laboratories is slowly expanding access to advanced tissue diagnostics.

Key Players

  • Roche (Ventana)
  • Abbott
  • Leica Biosystems (Danaher)
  • Bio-Techne
  • Agilent Technologies
  • Oxford Gene Technology
  • Thermo Fisher Scientific
  • Biocare Medical
  • ZytoVision
  • Empire Genomics

Segmentation

By Technique:

  • Fluorescence In Situ Hybridization
  • Chromogenic In Situ Hybridization

By Probe Type:

  • DNA Probes
  • RNA Probes

By Application:

  • Cancer Diagnostics
  • Infectious Diseases
  • Genetic Disorders
  • Neuroscience & Research
  • Others

By Geographic Coverage:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global In Situ Hybridization Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global In Situ Hybridization Market Outlook, 2020 - 2033

  • 3.1. Global In Situ Hybridization Market Outlook, by Technique, Value (US$ Bn), 2020-2033
    • 3.1.1. Fluorescence In Situ Hybridization
    • 3.1.2. Chromogenic In Situ Hybridization
  • 3.2. Global In Situ Hybridization Market Outlook, by Probe Type, Value (US$ Bn), 2020-2033
    • 3.2.1. DNA Probes
    • 3.2.2. RNA Probes
  • 3.3. Global In Situ Hybridization Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 3.3.1. Cancer Diagnostics
    • 3.3.2. Infectious Diseases
    • 3.3.3. Genetic Disorders
    • 3.3.4. Neuroscience & Research
    • 3.3.5. Others
  • 3.4. Global In Situ Hybridization Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America In Situ Hybridization Market Outlook, 2020 - 2033

  • 4.1. North America In Situ Hybridization Market Outlook, by Technique, Value (US$ Bn), 2020-2033
    • 4.1.1. Fluorescence In Situ Hybridization
    • 4.1.2. Chromogenic In Situ Hybridization
  • 4.2. North America In Situ Hybridization Market Outlook, by Probe Type, Value (US$ Bn), 2020-2033
    • 4.2.1. DNA Probes
    • 4.2.2. RNA Probes
  • 4.3. North America In Situ Hybridization Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 4.3.1. Cancer Diagnostics
    • 4.3.2. Infectious Diseases
    • 4.3.3. Genetic Disorders
    • 4.3.4. Neuroscience & Research
    • 4.3.5. Others
  • 4.4. North America In Situ Hybridization Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.4.1. U.S. In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 4.4.2. U.S. In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 4.4.3. U.S. In Situ Hybridization Market Outlook, by Application, 2020-2033
    • 4.4.4. Canada In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 4.4.5. Canada In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 4.4.6. Canada In Situ Hybridization Market Outlook, by Application, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe In Situ Hybridization Market Outlook, 2020 - 2033

  • 5.1. Europe In Situ Hybridization Market Outlook, by Technique, Value (US$ Bn), 2020-2033
    • 5.1.1. Fluorescence In Situ Hybridization
    • 5.1.2. Chromogenic In Situ Hybridization
  • 5.2. Europe In Situ Hybridization Market Outlook, by Probe Type, Value (US$ Bn), 2020-2033
    • 5.2.1. DNA Probes
    • 5.2.2. RNA Probes
  • 5.3. Europe In Situ Hybridization Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 5.3.1. Cancer Diagnostics
    • 5.3.2. Infectious Diseases
    • 5.3.3. Genetic Disorders
    • 5.3.4. Neuroscience & Research
    • 5.3.5. Others
  • 5.4. Europe In Situ Hybridization Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.4.1. Germany In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 5.4.2. Germany In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 5.4.3. Germany In Situ Hybridization Market Outlook, by Application, 2020-2033
    • 5.4.4. Italy In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 5.4.5. Italy In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 5.4.6. Italy In Situ Hybridization Market Outlook, by Application, 2020-2033
    • 5.4.7. France In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 5.4.8. France In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 5.4.9. France In Situ Hybridization Market Outlook, by Application, 2020-2033
    • 5.4.10. U.K. In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 5.4.11. U.K. In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 5.4.12. U.K. In Situ Hybridization Market Outlook, by Application, 2020-2033
    • 5.4.13. Spain In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 5.4.14. Spain In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 5.4.15. Spain In Situ Hybridization Market Outlook, by Application, 2020-2033
    • 5.4.16. Russia In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 5.4.17. Russia In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 5.4.18. Russia In Situ Hybridization Market Outlook, by Application, 2020-2033
    • 5.4.19. Rest of Europe In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 5.4.20. Rest of Europe In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 5.4.21. Rest of Europe In Situ Hybridization Market Outlook, by Application, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific In Situ Hybridization Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific In Situ Hybridization Market Outlook, by Technique, Value (US$ Bn), 2020-2033
    • 6.1.1. Fluorescence In Situ Hybridization
    • 6.1.2. Chromogenic In Situ Hybridization
  • 6.2. Asia Pacific In Situ Hybridization Market Outlook, by Probe Type, Value (US$ Bn), 2020-2033
    • 6.2.1. DNA Probes
    • 6.2.2. RNA Probes
  • 6.3. Asia Pacific In Situ Hybridization Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 6.3.1. Cancer Diagnostics
    • 6.3.2. Infectious Diseases
    • 6.3.3. Genetic Disorders
    • 6.3.4. Neuroscience & Research
    • 6.3.5. Others
  • 6.4. Asia Pacific In Situ Hybridization Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.4.1. China In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 6.4.2. China In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 6.4.3. China In Situ Hybridization Market Outlook, by Application, 2020-2033
    • 6.4.4. Japan In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 6.4.5. Japan In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 6.4.6. Japan In Situ Hybridization Market Outlook, by Application, 2020-2033
    • 6.4.7. South Korea In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 6.4.8. South Korea In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 6.4.9. South Korea In Situ Hybridization Market Outlook, by Application, 2020-2033
    • 6.4.10. India In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 6.4.11. India In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 6.4.12. India In Situ Hybridization Market Outlook, by Application, 2020-2033
    • 6.4.13. Southeast Asia In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 6.4.14. Southeast Asia In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 6.4.15. Southeast Asia In Situ Hybridization Market Outlook, by Application, 2020-2033
    • 6.4.16. Rest of SAO In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 6.4.17. Rest of SAO In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 6.4.18. Rest of SAO In Situ Hybridization Market Outlook, by Application, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America In Situ Hybridization Market Outlook, 2020 - 2033

  • 7.1. Latin America In Situ Hybridization Market Outlook, by Technique, Value (US$ Bn), 2020-2033
    • 7.1.1. Fluorescence In Situ Hybridization
    • 7.1.2. Chromogenic In Situ Hybridization
  • 7.2. Latin America In Situ Hybridization Market Outlook, by Probe Type, Value (US$ Bn), 2020-2033
    • 7.2.1. DNA Probes
    • 7.2.2. RNA Probes
  • 7.3. Latin America In Situ Hybridization Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 7.3.1. Cancer Diagnostics
    • 7.3.2. Infectious Diseases
    • 7.3.3. Genetic Disorders
    • 7.3.4. Neuroscience & Research
    • 7.3.5. Others
  • 7.4. Latin America In Situ Hybridization Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.4.1. Brazil In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 7.4.2. Brazil In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 7.4.3. Brazil In Situ Hybridization Market Outlook, by Application, 2020-2033
    • 7.4.4. Mexico In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 7.4.5. Mexico In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 7.4.6. Mexico In Situ Hybridization Market Outlook, by Application, 2020-2033
    • 7.4.7. Argentina In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 7.4.8. Argentina In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 7.4.9. Argentina In Situ Hybridization Market Outlook, by Application, 2020-2033
    • 7.4.10. Rest of LATAM In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 7.4.11. Rest of LATAM In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 7.4.12. Rest of LATAM In Situ Hybridization Market Outlook, by Application, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa In Situ Hybridization Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa In Situ Hybridization Market Outlook, by Technique, Value (US$ Bn), 2020-2033
    • 8.1.1. Fluorescence In Situ Hybridization
    • 8.1.2. Chromogenic In Situ Hybridization
  • 8.2. Middle East & Africa In Situ Hybridization Market Outlook, by Probe Type, Value (US$ Bn), 2020-2033
    • 8.2.1. DNA Probes
    • 8.2.2. RNA Probes
  • 8.3. Middle East & Africa In Situ Hybridization Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 8.3.1. Cancer Diagnostics
    • 8.3.2. Infectious Diseases
    • 8.3.3. Genetic Disorders
    • 8.3.4. Neuroscience & Research
    • 8.3.5. Others
  • 8.4. Middle East & Africa In Situ Hybridization Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.4.1. GCC In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 8.4.2. GCC In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 8.4.3. GCC In Situ Hybridization Market Outlook, by Application, 2020-2033
    • 8.4.4. South Africa In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 8.4.5. South Africa In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 8.4.6. South Africa In Situ Hybridization Market Outlook, by Application, 2020-2033
    • 8.4.7. Egypt In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 8.4.8. Egypt In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 8.4.9. Egypt In Situ Hybridization Market Outlook, by Application, 2020-2033
    • 8.4.10. Nigeria In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 8.4.11. Nigeria In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 8.4.12. Nigeria In Situ Hybridization Market Outlook, by Application, 2020-2033
    • 8.4.13. Rest of Middle East In Situ Hybridization Market Outlook, by Technique, 2020-2033
    • 8.4.14. Rest of Middle East In Situ Hybridization Market Outlook, by Probe Type, 2020-2033
    • 8.4.15. Rest of Middle East In Situ Hybridization Market Outlook, by Application, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Roche (Ventana)
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Abbott
    • 9.4.3. Leica Biosystems (Danaher)
    • 9.4.4. Bio-Techne
    • 9.4.5. Agilent Technologies
    • 9.4.6. Oxford Gene Technology
    • 9.4.7. Thermo Fisher Scientific
    • 9.4.8. Biocare Medical
    • 9.4.9. ZytoVision
    • 9.4.10. Empire Genomics

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!